Assessment of pregnancy outcomes in patients treated with Ajovy (fremanezumab): pregnancy registry (Teva migraine pregnancy registry)

Study identification

• EU PAS number:
  EUPAS38442
• Study ID:
  40047
• Official title and acronym:
  Assessment of pregnancy outcomes in patients treated with Ajovy (fremanezumab): pregnancy registry (Teva migraine pregnancy registry)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study status:
  Ongoing

Research institutions and networks

Institutions

Syneos Health

United Kingdom

Study timelines

Date when funding contract was signed

Planned: 10/09/2020

Study start date

Planned: 31/12/2020

Actual: 16/12/2020

Date of final study report

Planned: 31/12/2028

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Teva Branded Pharmaceutical Products R&D, Inc

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)